Weiss M
Medizinische Abteilung, Inselspital Bern.
Praxis (Bern 1994). 1995 May 2;84(18):526-32.
Magnesium acts as a cofactor of numerous enzymes and is important for the maintenance of a high intracellular potassium concentration and the transmembrane action potential. Of the total magnesium content of about 1000 mmol, only 0.3% are located in plasma. Hypomagnesemia and probable magnesium deficiency are found in 7 to 11% of hospitalized patients but are only rarely accompanied by relevant clinical symptoms. Prolonged diuretic therapy and secondary aldosteronism are frequent causes of hypomagnesemia in cardiology. Intravenous magnesium is a vasodilatator and prolongs the AH interval. In animal studies magnesium has been shown to have cardioprotective and platelet-inhibiting properties. The only verified indication for intravenous magnesium is the initial treatment of torsade de pointes. Magnesium may suppress digitalis-induced tachyarrhythmias and convert paroxysmal supraventricular tachycardia and monomorphic ventricular tachycardia to sinus rhythm. Its role in the treatment of acute myocardial infarction and of ventricular arrhythmias in congestive heart failure is unclear.
镁作为多种酶的辅助因子,对于维持细胞内高钾浓度和跨膜动作电位至关重要。在总量约1000毫摩尔的镁中,仅有0.3%存在于血浆中。7%至11%的住院患者存在低镁血症及可能的镁缺乏,但很少伴有相关临床症状。在心脏病学领域,长期利尿治疗和继发性醛固酮增多症是低镁血症的常见原因。静脉注射镁是一种血管扩张剂,可延长AH间期。动物研究表明镁具有心脏保护和抑制血小板的特性。静脉注射镁唯一经证实的适应证是尖端扭转型室速的初始治疗。镁可能抑制洋地黄引起的快速心律失常,并将阵发性室上性心动过速和单形性室性心动过速转为窦性心律。其在急性心肌梗死和充血性心力衰竭室性心律失常治疗中的作用尚不清楚。